PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

NTM in Oncology: Dual Beta-Lactam Signals Warrant Study

nontuberculous mycobacteriaMycobacterium avium complexMycobacterium abscessusmeropenemceftarolineimipenem-cilastatindual beta-lactambedaquilineoncologyretrospective cohortantimicrobial stewardshipOPAT Infectious Disease / Antimicrobials
Also in Oncology

Background Information

NTM infections in cancer patients demand complex treatment approaches.

Nontuberculous mycobacteria (NTM) infections are increasing, and oncology patients represent a unique population at risk. 93 patients were studied, with Mycobacterium avium complex and Mycobacterium abscessus as common pathogens. 53% received therapy, often requiring regimen modifications. The findings highlight treatment challenges in oncology patients, noting dual β-lactam therapy's role. Limitations include the single-center retrospective design. NTM infections in oncology require complex, adaptive treatment strategies.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Pasikhova Y, Snyder M, Morrison A, Handley G, Syed M, Cannella AP

Citation: Pasikhova Y, Snyder M, Morrison A, et al. Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida. Open forum infectious diseases. 2026;13(8):ofag467. doi:10.1093/ofid/ofag467

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.